Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Publication Title,Pubmed Url,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId,Dataset View_id
PublicationView,CA214297,10.1007/s10549-023-06998-w,Breast Cancer Res Treat,37318638,Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells,https://pubmed.ncbi.nlm.nih.gov/37318638,2023,"Circulating Tumor Cells (Ctcs), Fulvestrant Resistance, Er + metastatic Breast Cancer, Elacestrant, Selective Estrogen Receptor Degrader (Serd)","Taronish D Dubash, Aditya Bardia, Brian Chirn, Brittany A Reeves, Joseph A LiCausi, Risa Burr, Ben S Wittner, Sumit Rai, Hitisha Patel, Teeru Bihani, Heike Arlt, Francois-Clement Bidard, Virginia G Kaklamani, Philippe Aftimos, Javier Cortés, Simona Scartoni, Alessio Fiascarelli, Monica Binaschi, Nassir Habboubi, A John Iafrate, Mehmet Toner, Daniel A Haber, Shyamala Maheswaran","Purpose: Metastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refractory. Elacestrant, a new generation FDA-approved oral selective estrogen receptor degrader (SERD) and antagonist, has demonstrated efficacy in a subset of women with advanced HR+breast cancer, but there are few patient-derived models to character(Read more on Pubmed)","Clinical Study, Patient Derived Xenograft, Immunohistochemistry Staining Method, qPCR","Breast Adenocarcinoma, Triple-Negative Breast Carcinoma",Breast,Not Applicable,Open Access,37318638,20a7b1e6-bd30-4eed-9dc7-f3cc6fa9ade2,syn52543319,37318638
